In brief
Robert Langer argues that major advances in medicine come from building a new enabling tool, such as a way to slowly release a drug or to grow tissue on a scaffold, and then patiently turning it into products. He describes how that work took decades, billions of dollars and many collaborators. In his view, the science needs patents, strong business partners and sustained funding to reach patients.
The central tension is between the long odds and the payoff. Langer describes early journal rejections, work that few people believed in, and 28 years between his first angiogenesis (blood vessel growth) paper and the approval of Avastin. Alongside this he stresses people: students, business leaders and philanthropists with a clear vision. He is optimistic about tissue engineering, CRISPR and AI, but expects progress to be stepwise.
Questions
What is drug delivery and why does it matter?
Langer defines it as getting a drug to go where you want it, at the level you want, safely. It matters because it covers problems like targeting only cancer cells, getting insulin in without injections, and crossing the blood-brain barrier.
How did blocking blood vessels become a cancer treatment?
Langer explains that tumors need new blood vessels to grow and spread, so cutting off that supply can starve them. His postdoc advisor Judah Folkman proposed the idea, many thought it was crazy, and Avastin was approved in 2004.
Can scientists grow human tissue and organs today?
Langer says skin has been grown and approved by the FDA for burn victims and diabetic skin ulcers, and new blood vessels are in late-stage trials. Whole organs like livers and kidneys are still early, and he thinks full regeneration may take hundreds of years.
Why does developing a new drug cost so much?
Langer cites Tufts for a cost of over $2 billion per new drug. The largest part is human clinical trials, which must prove safety and effectiveness in progressively larger groups of patients.
Will AI help design new medicines?
Langer thinks AI can help, for example by studying thousands of tested chemicals to spot what the working ones share and predicting what to test next. He also expects it to play a role in almost everything eventually.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Robert Langer and Judah Folkman published a 1976 paper in Science describing some of the first angiogenesis (blood vessel growth) inhibitors, isolated from cartilage.
“we found one, it wasn't purified, but we found one that did work, and that paper, that was the paper I mentioned in science in 1976.”
0:15:33 · Bob Langer · Angiogenesis · 1976
Avastin, the first approved drug of this angiogenesis-blocking type, was approved by the FDA in 2004, 28 years after the 1976 work.
“in 2004, 28 years after we started, the first one of those, Avastin, got approved by the FDA.”
0:18:25 · Bob Langer · Avastin approval · 2004
Langer explains that blood vessels grow into tumors and help them grow larger and spread.
“And if you have cancer, blood vessels grow into the tumor, and that's part of what enables the tumor to get bigger.”
0:14:20 · Bob Langer · Tumor angiogenesis
Langer says that when Judah Folkman first proposed starving tumors by cutting off blood vessels, many people thought he was crazy.
“when Dr. Folkman, my boss, first proposed it, it wasn't, a lot of people thought he was pretty crazy.”
0:19:42 · Bob Langer · Folkman's hypothesis
Langer cites Tufts as estimating that developing a new drug costs over $2 billion.
“which according to tufts to make a new drug costs over $2 billion right now and nobody would even come close to giving you that money”
0:38:52 · Bob Langer · Drug costs
Langer says human clinical trials are almost always the largest expense in drug development.
“usually proving that something new is safe and effective in people is almost always the biggest expense.”
0:39:59 · Bob Langer · Clinical trials
Langer describes phase one trials as testing safety and phase two trials as testing effectiveness, each in a small number of patients.
“A phase one trial to show that it's safe in small number of patients. A phase two trial to show that it's effective in a small number of patients”
0:40:34 · Bob Langer · Clinical trial phases
Langer says phase three trials test safety and effectiveness in a large number of patients.
“and a phase three trial to show that it's safe and effective in a large number of patients”
0:40:34 · Bob Langer · Clinical trial phases
Langer's lab has encapsulated insulin-producing beta cells so they are protected while still responding to glucose.
“one of the things that we've done is encapsulate what are called beta cells. Those are insulin producing cells in a way that they're safe and protected.”
0:24:19 · Bob Langer · Diabetes therapy
Langer's lab has made microchips that release a drug when sent a signal.
“we, for example, have made what I'll call intelligent microchips that can, you know, where you can send a signal and, you know, release drug in response to that signal.”
0:24:59 · Bob Langer · Smart drug delivery
Langer says he and Jay Vacanti pioneered the use of scaffolds on which cells grow for tissue engineering.
“having generally some type of scaffold. That's what Jay Vacanti and I started many, many years ago.”
0:29:31 · Bob Langer · Tissue engineering
Langer says engineered skin has been approved by the FDA.
“skin's already been made and approved by the FDA. There are advanced clinical trials, like what are called phase three trials”
0:31:11 · Bob Langer · Engineered skin
Langer says engineered skin products have been approved for burn victims and patients with diabetic skin ulcers.
“they've been approved for burn victims and for patients with diabetic skin ulcers.”
0:31:58 · Bob Langer · Engineered skin
Langer describes CRISPR as built on a bacterial mechanism for destroying viruses, which became a tool to cut and paste genes.
“there's a mechanism by which bacteria are able to destroy viruses and that understanding that leads to machinery to put, you know, to sort of cut and paste genes”
0:35:52 · Bob Langer · CRISPR
Langer says patent applicants negotiate with the United States Patent and Trademark Office, which may reject applications several times.
“And then you go back and forth with the USPTO, that's the United States Patent and Trademark Office.”
0:42:21 · Bob Langer · Patent process
Langer says his lab writes a disclosure for MIT's technology transfer office, which passes it to patent attorneys.
“we write something up what's called a disclosure we give it to mit's technology transfer office they then give it to some patent attorneys”
0:41:46 · Bob Langer · Technology transfer
Lex Fridman states that Robert Langer has over 295,000 citations and an H-index of 269.
“you have over 295 ,000 citations, an H-index of 269. You're one of the most cited people in history and the most cited engineer in history.”
0:05:46 · Lex Fridman · Citations · 2020
Lex Fridman says Robert Langer has helped launch about 40 companies with an estimated combined value of $23 billion.
“So you've been part of launching 40 companies together worth, again, numbers could be outdated, but an estimated $23 billion.”
0:42:37 · Lex Fridman · Startups · 2020
Langer says his lab works with the Gates Foundation to extend medicines to people in the developing world.
“which is something that our lab has been doing with the gates foundation or trying to do”
0:27:43 · Bob Langer · Global health
Langer says philanthropist David Koch funded cancer research partly because he had prostate cancer.
“David Koch was very interested in cancer research. And part of that was that he had cancer and prostate cancer.”
0:52:46 · Bob Langer · Philanthropy
Langer says Bill Gates chose to focus his philanthropy on medicines and vaccines for people in the developing world.
“he thought about helping people in the developing world and medicines and different things like that, like vaccines”
0:53:19 · Bob Langer · Philanthropy
MIT's mechanical engineering department hired Gio Traverso, a molecular biologist and gastroenterologist who had been a fellow with Langer.
“mechanical engineering department just had a search and they hired Gio Traverso, who was one of my, he was a fellow with me, but he's actually a molecular biologist and a gastroenterologist.”
0:56:16 · Bob Langer · Academic hiring
David Edwards, a former Langer postdoc and Harvard professor, started Cafe Art Sciences.
“You have to go to see some of David Edwards' stuff. He was one of my postdocs and he's a professor at Harvard, but he also started Cafe Art Sciences.”
0:59:19 · Bob Langer · Cafe Art Sciences
Langer says about 18 of his former students are in the National Academy of Engineering and 16 in the National Academy of Medicine.
“I think 18 are in the National Academy of Engineering, 16 in the National Academy of Medicine.”
1:00:13 · Bob Langer · Student outcomes